Labcorp (LH)
(Delayed Data from NYSE)
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:10 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:10 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability
by Zacks Equity Research
PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.
BD (BDX) Product Gets FDA Nod, Patient Outcome to Get a Boost
by Zacks Equity Research
Regulatory clearance for BD's (BDX) Kiestra IdentifA system is expected to lead to better patient management via automated sample processing and MALDI target preparation.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS), owing to consistent improvement in its consumer-centric digital solutions and raised guidance.
NuVasive (NUVA) Gets FDA Nod for Attrax Putty Expanded Use
by Zacks Equity Research
NuVasive's (NUVA) Attrax Putty is the first and only synthetic biologic to receive 510(k) indications for use in interbody fusions of the thoracolumbar spine.
4 Momentum Picks Screened on Driehaus Strategy
by Nitish Marwah
COWN, LH, BBWI, and ARCB qualified as the momentum picks for the day, using the Driehaus strategy.
Stryker (SYK) to Boost Digital Capabilities With New Buyout
by Zacks Equity Research
Stryker (SYK) inks a deal with Vocera to enhance its digital healthcare offerings.
Thermo Fisher (TMO) Completes Buyout of PeproTech for $1.85B
by Zacks Equity Research
Thermo Fisher's (TMO) recent acquisition will boost its capabilities to serve in the high-growth cell and gene therapy market.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada
by Zacks Equity Research
PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.
Best Value Stocks to Buy for January 6th
by Zacks Equity Research
M, LH, and SEKEY made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2022
LabCorp (LH) Stock Moves -1.25%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $286.57 in the latest trading session, marking a -1.25% move from the prior day.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong segmental performances are driving the top line for STERIS (STE).
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.
Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.
Here's Why You Should Add Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
LabCorp (LH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.
Quidel's (QDEL) Antigen Tests Successful in Omicron Detection
by Zacks Equity Research
The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.
PacBio's (PACB) New Surveillance Kit Successful Against Omicron
by Zacks Equity Research
PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.